Health insurance; modifying copayment cap of certain insulin supply; requiring copayment cap for certain diabetes equipment and supplies; requiring reduction in cost-sharing amount for certain supply and equipment. Effective date.
Impact
The implications of SB142 are significant for state laws governing health insurance and diabetes management. By establishing maximum copayment amounts, the bill aims to improve accessibility and affordability of essential diabetes treatments for Oklahomans. This legislative change is particularly important given the rising costs of insulin and diabetes supplies, which have been a point of concern for many patients and healthcare advocates. Furthermore, the bill empowers the Insurance Commissioner to enforce compliance, thereby ensuring that health benefit plans adhere to these new copayment mandates.
Summary
Senate Bill 142, introduced by Senator Hicks, amends Oklahoma's health insurance regulations to modify the copayment cap specifically for insulin and related diabetes supplies. The bill mandates that state health benefit plans must cap the copayment for a thirty-day supply of insulin at no more than $25, with similar caps for diabetes equipment that exceeds $35. Additionally, it provides that if the cost of any diabetes-related equipment or supply is less than the specified copayment cap, the insurance company must reduce the cost-sharing to that lesser amount. This change is intended to alleviate financial burdens for individuals reliant on insulin and diabetes supplies.
Contention
Notably, there could be some points of contention surrounding SB142. Health insurance providers may express concerns about the financial implications of the mandated copayment caps, arguing that they could lead to increased premiums or other cost-shifting measures. Additionally, the bill's effective date of November 1, 2023, gives stakeholders limited time to adapt, which could provoke pushback from insurers who need to restructure their policy frameworks to comply with the new standards. Furthermore, discussions around healthcare costs and insurance often involve differing opinions on how to balance patient affordability with sustainable insurance practices.
Carry Over
Health insurance; modifying copayment cap of certain insulin supply; requiring copayment cap for certain diabetes equipment and supplies; requiring reduction in cost-sharing amount for certain supply and equipment. Effective date.
An Act to amend and reenact ยงยง 38.2-3407.15:5 and 38.2-3418.10 of the Code of Virginia, relating to health insurance; cost-sharing payments for insulin and diabetes equipment and supplies; limit.
Caps amount payable for 30 day supply of equipment/supplies for insulin administration/glucose monitoring at $25 or equipment designed to last more than 30 days with no deductible commencing January 1, 2027.
Caps amount payable for 30 day supply of equipment/supplies for insulin administration/glucose monitoring at $25 or equipment designed to last more than 30 days with no deductible commencing January 1, 2027.
Caps amount payable for 30 day supply of equipment/supplies for insulin administration/glucose monitoring at $25 or equipment designed to last more than 30 days with no deductible commencing January 1, 2026.
Caps amount payable for 30 day supply of equipment/supplies for insulin administration/glucose monitoring at $25 or equipment designed to last more than 30 days with no deductible commencing January 1, 2026.